Guillermo Padilla-Pineda, MD
Infectious Disease · Shreveport, LANPI 1124229265
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,508 of the $106,202 with a category attached, or 80.5%. 24 manufacturers reported payments, led by Melinta Therapeutics, LLC at 47.5% of the total. Reporting peaked in 2019 at $28,100 and has fallen 80.2% since, to $5,560 in 2025. Among infectious disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $230.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$50K
- La Jolla Pharmaceutical Company$22K
- Tetraphase Pharmaceuticals, Inc.$16K
- Merck$12K
- Astellas Pharma US Inc$1K
- Paratek Pharmaceuticals, Inc.$1K
- plus $3K from 18 others
What the payments were for
- Speaking & faculty fees$85,50881%
- Travel & lodging$4,5304%
- Food & beverage$15,47515%
- Education$6891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 110 | $50,488 |
| La Jolla Pharmaceutical Company | 50 | $22,426 |
| Tetraphase Pharmaceuticals, Inc. | 29 | $15,734 |
| Merck | 97 | $11,902 |
| Astellas Pharma US Inc | 38 | $1,129 |
| Paratek Pharmaceuticals, Inc. | 38 | $1,122 |
| Insmed, Inc. | 20 | $917 |
| AstraZeneca(2 entities) | 3 | $374 |
| Mallinckrodt Hospital Products Inc. | 7 | $374 |
| Shionogi Inc | 15 | $335 |
| Gilead | 9 | $306 |
| Johnson & Johnson(2 entities) | 14 | $274 |
| Theratechnologies Inc. | 7 | $179 |
| Aimmune Therapeutics, Inc. | 4 | $140 |
| Viiv Healthcare Company | 6 | $109 |
| Veloxis Pharmaceuticals, Inc. | 1 | $81 |
| Pfizer | 4 | $73 |
| Janssen Products, LP | 1 | $70 |
| EMD Serono, Inc. | 3 | $64 |
| Organogenesis Inc. | 1 | $27 |
| Electromed, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,202 in reported general payments places this provider in the 95th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 84 | $90,127 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 16 | $59,166 |
| DescovyEmtricitabine/Tenofov Alafenam | 20 | $43,517 |
| IsentressRaltegravir Potassium | 20 | $38,328 |
| PrezcobixDarunavir/Cobicistat | 12 | $28,938 |
| ErtapenemErtapenem Sodium | 55 | $14,529 |
| CeftriaxoneCeftriaxone Sodium | 17 | $3,277 |
| Doxycycline Hyclate | 68 | $1,662 |
| Cefepime Hcl | 13 | $1,616 |
| Levofloxacin | 36 | $1,315 |
| Cefazolin Sodium | 25 | $1,240 |
| Rifampin | 14 | $923 |
| AbacavirAbacavir Sulfate | 11 | $807 |
| Ampicillin Trihydrate | 12 | $378 |
| Cephalexin | 31 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq | $109 | $59,16616 claims |
| GileadDescovy | $306 | $43,51720 claims |
| MerckIsentress | $11,902 | $38,32820 claims |
| Johnson & JohnsonPrezcobix | $274 | $28,93812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 infectious disease providers in Louisiana.
Other infectious disease in Shreveport
- Hector Brunet RodriguezShreveport$592K
- Jihad El-HayekShreveport$11K
- Halim Abou FaycalShreveport$9K
- Paulette Pinargote CornejoShreveport$6K
- Mohammad AlamShreveport$5K
- Alexandre MalekShreveport$5K
- John ToddShreveport$4K
- Gerardo NegronShreveport$2K
- Aline ArifShreveport$2K
- Raymond CoghlanShreveport$601
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.